Richard Furman, M.D., is Director of the CLL Research Center at Weill Cornell Medicine and a member of the Lymphoma Service in the Division of Hematology/Oncology.  His area of focus is on the development of non-chemotherapeutic approaches to treating CLL and Waldenström’s macroglobulinemia, and he has played an integral part in the development of the novel BTK, PI3K, and BCL-2 inhibitors as treatments.